Advertisement

This Week In HIV Research

News

This Week in HIV Research: Determinants of Cognitive Impairment, and Discovery of 'Teenage' Broadly Neutralizing Antibody

April 8, 2016

This week, a new study highlights some of the determinants of cognitive impairment among middle-aged men living with HIV. Another study discovers an immature antibody that may provide clues for developing broadly neutralizing antibodies capable of inhibiting HIV. Also, Descovy, a new drug containing the updated version of tenofovir -- tenofovir alafenamide (TAF) -- was approved by the FDA. To beat HIV, you have to follow the science!


Comorbidities

Determinants of Reduced Cognitive Performance in Middle-Aged Men Living With HIV on Treatment

Determinants of Reduced Cognitive Performance in Middle-Aged Men Living With HIV on Treatment

A number of factors, not all of them related to HIV, may reduce cognitive performance in people living with HIV, including more severe immune deficiency, cardiovascular/metabolic factors, cannabis use, and symptoms of depression, according to a study published in AIDS.

Researchers followed 103 individuals living with HIV who were on treatment and had undetectable viral loads for at least one year, along with 74 HIV-negative controls. All study participants were at least 45 years old and male.

Neuropsychological assessments were conducted by trained neuropsychologists and evaluated six areas commonly affected by HIV-associated cognitive impairment: fluency, attention, information processing speed, executive function, memory, and motor function.

Based on these assessments, cognitive impairment and performance were then determined by multivariate normative comparison (MNC), which is a statistical method of analysis. In total, 17% of the HIV-positive group was diagnosed with cognitive impairment.

Using MNC as a continuous variable for analysis, the researchers found that the determinants for decreased cognitive performance included:

  • Cannabis use.
  • History of prior cardiovascular disease.
  • Impaired renal function.
  • Type-2 diabetes.
  • Having an above-normal waist-to-hip ratio.
  • Symptoms of depression.
  • Lower nadir CD4+ cell count.

"These [determinants] are likely to gain increased importance as the population of people living with HIV continues to age," the researchers concluded.

Read: This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine


Advertisement

Vaccine Research

Researchers Get First-Ever Glimpse of "Teenage" HIV-Neutralizing Antibody

Researchers at the Scripps Research Institute have identified for the first time an immature or "teenage" version of a broadly neutralizing antibody (bNAb) capable of inhibiting HIV, according to a study published online ahead of its release in the journal Immunity.

Broadly neutralizing antibodies continue to be discovered and studied, primarily in the development of an HIV vaccine, but also as part of a potential treatment strategy.

The teenage antibody came from a Chinese individual living with HIV who is also an elite controller, a person living with HIV who can maintain a very low viral load without treatment.

"This is actually the first example of how we can go back to the really early stage to see how this antibody lineage was born and can develop," said co-senior author Jiang Zhu, Ph.D., according to the study press release.

The discovery of this teenage antibody sheds light on the evolution of broadly neutralizing antibodies and further guides researchers in engineering an effective HIV vaccine.


Treatment

Descovy, New HIV Drug Containing Tenofovir Alafenamide, Approved by FDA

On April 4, the U.S. Food and Drug Administration (FDA) approved emtricitabine/tenofovir alafenamide (F/TAF), which will be marketed as Descovy, in a fixed-dose combination for the treatment of HIV in adults and adolescents over 12.

Descovy is the third approved HIV drug to include TAF, which has been shown to have better bone and kidney safety than its predecessor tenofovir disoproxil fumarate (TDF, Viread). It essentially replaces the TDF in tenofovir/emtricitabine (F/TDF, Truvada).

Descovy is indicated to be used in combination with other HIV antiretrovirals; however, it is not indicated for use as pre-exposure prophylaxis (PrEP), according to the approval press release.

Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.

Follow Warren on Twitter: @WarrenAtTheBody.


Copyright © 2016 Remedy Health Media, LLC. All rights reserved.


Related Stories

This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine
This Week in HIV Research: Reducing the Cost of Hepatitis C Cures, and Atazanavir During Pregnancy Linked to Developmental Delays
This Week in HIV Research: Racial Disparity in Retention in Care Develops Over Time, and Preventing Half of New Infections by 2025



This article was provided by TheBodyPRO.com.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.